Yahoo Finance

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

ST. LOUIS, December 15, 2025--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic ...
Business Wire

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...
C&EN

Artificial cofactor system sustains central metabolism in bacteria

Many enzymes require cofactors such as nicotinamide adenosine dinucleotide (NAD +) or nicotinamide adenosine dinucleotide phosphate (NADP +) to shuttle electrons between reactions. Artificial redox ...
Business Wire

Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been ...
VentureBeat

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.